Weed (BUDZ) Accumulated Expenses (2010 - 2026)

Weed's (BUDZ) quarterly Accumulated Expenses came in at $42326.0 in Q1 2026, down 82.2% year-on-year from $237750.0 in Q1 2025, and down 61.97% quarter-over-quarter from $111300.0 in Q4 2025.

Weed (BUDZ) Accumulated Expenses (2010 - 2026) Analysis & Trends

Weed's Accumulated Expenses history runs 13 years deep, the most recent figure standing at $42326.0 for Q1 2026.

  • On a quarterly basis, Accumulated Expenses fell 82.2% year-over-year to $42326.0 in Q1 2026; TTM through Mar 2026 was $42326.0, a 82.2% decrease from a year earlier, with the FY2025 full-year figure at $111300.0, up 31.1% from the prior year.
  • Accumulated Expenses eased to $42326.0 in Q1 2026 per BUDZ's latest filing, from $111300.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $430342.0 in Q2 2023 and bottomed at $13000.0 in Q4 2023.
  • The 5-year median for Accumulated Expenses is $98100.0 (2025), against an average of $149581.9.
  • Across the five-year window, Accumulated Expenses tumbled 92.03% in 2022 and jumped 1628.28% in 2023, its largest moves.
  • Year by year, Accumulated Expenses stood at $42266.0 in 2022, then tumbled by 69.24% to $13000.0 in 2023, then surged by 553.08% to $84900.0 in 2024, then jumped by 31.1% to $111300.0 in 2025, then sank by 61.97% to $42326.0 in 2026.
  • Per Business Quant, the three latest BUDZ Accumulated Expenses figures stand at $42326.0 (Q1 2026), $111300.0 (Q4 2025), and $27500.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Weed 3.72 Mn 3.72 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 42,326.00
Dec 31, 2025 111,300.00
Sep 30, 2025 27,500.00
Jun 30, 2025 98,100.00
Mar 31, 2025 237,750.00
Dec 31, 2024 84,900.00
Sep 30, 2024 88,149.00
Jun 30, 2024 139,500.00
Mar 31, 2024 128,879.00
Dec 31, 2023 13,000.00
Sep 30, 2023 213,500.00
Jun 30, 2023 430,342.00
Mar 31, 2023 45,481.00
Dec 31, 2022 42,266.00
Sep 30, 2022 425,750.00
Jun 30, 2022 24,900.00
Mar 31, 2022 389,250.00
Dec 31, 2021 16,500.00
Sep 30, 2021 329,750.00
Jun 30, 2021 312,250.00